JANX Q1 2024 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-38.9% YoY

Gross Profit

$720,00057.5% margin

Operating Income

-$20M-1610.3% margin

Net Income

-$15M-1178.9% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

-49.1%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$689M

Total Liabilities

$33M

Stockholders' Equity

$656M

Cash & Equivalents

$213M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-38.9%
Gross Profit	$720,000	-$14M	+105.2%
Operating Income	-$20M	-$20M	+0.6%
Net Income	-$15M	-$17M	+15.5%